Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Biochemistry

• Publication date

  1994-05-10

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/BI00184A014PMID 7910034
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.

  1993cited by this paper
• A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.

  1993cited by this paper
• Selection of an active single chain Fv antibody from a protein linker library prepared by enzymatic inverse PCR.

  1993cited by this paper
• A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies.

  1992cited by this paper
• Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.

  1992cited by this paper
• Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

  1992cited by this paper
• Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.

  1991cited by this paper
• Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas.

  1991cited by this paper
• Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli.

  1991cited by this paper
• B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.

  1991cited by this paper
• Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL.

  1991cited by this paper
• Recombinant toxins for cancer treatment.

  1991cited by this paper
• A comparison of strategies to stabilize immunoglobulin Fv-fragments.

  1990cited by this paper
• A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin

  1989cited by this paper
• Single-chain antigen-binding proteins.

  1988cited by this paper
• Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

  1988cited by this paper
• Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes.

  1986cited by this paper
• Rapid and efficient site-specific mutagenesis without phenotypic selection.

  1985cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy

  2024cites this paper
• Enhancing the cytotoxicity of immunotoxins by facilitating their dissociation from target receptors under the reducing conditions of the endocytic pathway.

  2024cites this paper
• A tri-specific killer engager against mesothelin targets NK cells towards lung cancer

  2023cites this paper
• Next generation of multispecific antibody engineering.

  2023cites this paper
• TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life

  2023cites this paper
• Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy

  2023cites this paper
• Generation of recombinant antibodies by mammalian expression system for detecting S-metolachlor in environmental waters.

  2021cites this paper
• Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries

  2021cites this paper
• New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab.

  2020cites this paper
• Targeting Receptors on Cancer Cells with Protein Toxins

  2020cites this paper
• Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody

  2020cites this paper
• Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval.

  2019cites this paper
• Effect of allotypic variation of human IgG1 on the thermal stability of disulfide-linked knobs-into-holes mutants of the Fc for stable bispecific antibody design

  2019cites this paper
• Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease

  2019cites this paper
• Hairy cell leukemia: present and future directions

  2019cites this paper
• Update on hairy cell leukemia.

  2018cites this paper
• Transcytosis of payloads that are non-covalently complexed to bispecific antibodies across the hCMEC/D3 blood-brain barrier model

  2018cites this paper
• Roles of the disulfide bond between the variable and the constant domains of rabbit immunoglobulin kappa chains in thermal stability and affinity

  2018cites this paper
• Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies

  2018cites this paper
• Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds

  2018cites this paper
• BL22: A Milestone in Targeting CD22

  2017cites this paper
• Engineered hapten‐binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery

  2016cites this paper
• Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2

  2016cites this paper
• The future of antiviral immunotoxins

  2016cites this paper
• Generación de anticuerpos de dominio único específicos para CD105 humano

  2016cites this paper
• Novel strategy for a bispecific antibody: induction of dual target internalization and degradation

  2016cites this paper
• A novel variable antibody fragment dimerized by leucine zippers with enhanced neutralizing potency against rabies virus G protein compared to its corresponding single-chain variable antibody fragment.

  2015cites this paper
• Engineering Antibody Fragments for Intracellular Applications

  2015cites this paper
• Challenges for Therapeutic Application of Pseudomonas Exotoxin-Based Immunotoxins

  2015cites this paper
• Glioma

  2015cites this paper
• Immunoconjugates in the management of hairy cell leukemia.

  2015cites this paper
• Resistance to Immunotoxins in Cancer Therapy

  2015influential citation
• A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties*

  2014cites this paper
• A NOVEL GLYCOENGINEERED BISPECIFIC ANTIBODY FORMAT FOR TARGETED INHIBITION OF EGFR AND IGF-1R DEMONSTRATING UNIQUE MOLECULAR PROPERTIES

  2014cites this paper
• Design, Development, and Characterization of Recombinant Immunotoxins Targeting HER2/neu

  2013cites this paper
• Immunotoxins: The Role of the Toxin †

  2013cites this paper
• CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes

  2013cites this paper
• Hairy Cell Leukemia—New Genes, New Targets

  2013cites this paper
• Folding and aggregation of a multi-domain engineered immunotoxin

  2013cites this paper
• Classic Immunotoxins with Plant or Microbial Toxins

  2013cites this paper
• A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency.

  2012cites this paper
• Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation.

  2012cites this paper
• Purification of clinical-grade disulfide stabilized antibody fragment variable—Pseudomonas exotoxin conjugate (dsFv-PE38) expressed in Escherichia coli

  2012cites this paper
• Metabolic engineering of recombinant protein secretion by Saccharomyces cerevisiae.

  2012cites this paper
• Monoclonal antibody therapy for malignant glioma.

  2012cites this paper
• Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.

  2012cites this paper
• A guide to taming a toxin – recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

  2011cites this paper
• Preparation of Human Antibody Fragments Against Rabies Virus Based on Ribosome Display Technology*: Preparation of Human Antibody Fragments Against Rabies Virus Based on Ribosome Display Technology*

  2011cites this paper
• Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

  2011cites this paper
• TRISPECIFIC THERAPEUTICS AGAINST ACUTE MYELOID LEUKAEMIA

  2011influential citation
• Directed evolution and structural analysis of an OB-fold domain towards a specifc binding reagent

  2011influential citation
• A modular IgG-scFv bispecific antibody topology.

  2010cites this paper
• Expression of a Functional zipFv Antibody Fragment and Its Fusions with Alkaline Phosphatase in the Cytoplasm of an Escherichia coli

  2010cites this paper
• Antibody Engineering in Agricultural Biotechnology

  2010cites this paper
• Antibody Engineering for Biosensor Applications

  2010cites this paper
• Disulfide-Stabilized Fv Fragments

  2010cites this paper
• Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

  2009cites this paper
• Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.

  2009cites this paper
• Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains.

  2008cites this paper
• Engineering intracellular antibody libraries

  2008cites this paper
• Molecular targets and targeted therapies for malignant mesothelioma.

  2008cites this paper
• A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells

  2008cites this paper
• Preparing recombinant single chain antibodies

  2008cites this paper
• Releasable PEGylation of proteins with customized linkers.

  2008cites this paper
• Modeling Recombinant Immunotoxin Efficacies in Solid Tumors

  2008cites this paper
• Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

  2007cites this paper
• Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.

  2007cites this paper
• chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.

  2007cites this paper
• Potential applications of designed ankyrin repeat proteins in diagnostics and therapeutics.

  2007cites this paper
• Immunotoxins in the treatment of hematologic malignancies.

  2006cites this paper
• Immunotoxins for targeted cancer therapy

  2006cites this paper
• Mono and bivalent binding of a scFv and covalent diabody to murine laminin-1 using radioiodinated proteins and SPR measurements: effects on tissue retention in vivo.

  2006cites this paper
• CYTOTOXIC AND ANTITUMOR ACTIVITY OF A RECOMBINANT FRAGMENT AND TRUNCATED PSEUDOMONAS EXOTOXIN IMMUNOTOXIN COMPOSED OF DISULFIDE-STABILIZED ANTI-TAC FV

  2006cites this paper
• Immunotoxins in the treatment of refractory hairy cell leukemia.

  2006cites this paper
• The role of interface framework residues in determining antibody VH/VL interaction strength and antigen‐binding affinity

  2006cites this paper
• HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity

  2005cites this paper
• PROTEIN MICROARRAYS BASED ON SINGLE FRAMEWORK RECOMBINANT ANTIBODY FRAGMENTS (SINFABS)

  2005cites this paper
• Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.

  2005cites this paper
• Production of bifunctional proteins by Aspergillus awamori

  2005cites this paper
• Development of a phage displayed disulfide-stabilized Fv fragment vaccine against Vibrio anguillarum.

  2005cites this paper
• Effective lysis of lymphoma cells with a stabilised bispecific single‐chain Fv antibody against CD19 and FcγRIII (CD16)

  2005cites this paper
• Pharmacokinetics of Antibodies and Immunotoxins in Mice and Humans

  2004cites this paper
• Mesothelin

  2004cites this paper
• In Vitro and in Vivo Cytotoxic Activities of Recombinant Immunotoxin 8H9(Fv)-PE38 against Breast Cancer, Osteosarcoma, and Neuroblastoma

  2004cites this paper
• Immunotoxins and other conjugates: preparation and general characteristics.

  2004cites this paper
• Recombinant immunotoxins for the treatment of haematological malignancies

  2004cites this paper
• Design and cancer-targeting potential of antibody-based molecules directed against carcinoembryonic antigen.

  2004cites this paper
• Recombinant toxins for the treatment of cancer.

  2003cites this paper
• Immunobiological treatments of hairy-cell leukaemia.

  2003cites this paper
• The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi

  2003cites this paper
• Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin.

  2002cites this paper
• Antibody–Toxin and Growth Factor–Toxin Fusion Proteins

  2002cites this paper
• Recombinant fusion toxins for cancer treatment

  2002cites this paper
• Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.

  2001cites this paper
• Production of an anti-prostate-specific antigen single-chain antibody fragment from Pichia pastoris.

  2001cites this paper
• Recombinant immunotoxins for cancer therapy

  2001cites this paper
• Isolation of new anti‐CD30 scFvs from DNA‐immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin

  2001cites this paper
• Stability engineering of antibody single-chain Fv fragments.

  2001cites this paper
• Stabilization Strategies and Application of Recombinant Fvs and Fv Fusion Proteins

  2001cites this paper
• Antiferritin single-chain Fv fragment is a functional protein with properties of a partially structured state: comparison with the completely folded V(L) domain.

  2000cites this paper